Other sections: Abbreviations Commentaries Diabetes Info Dictionary Magazines & Journals Press Releases Websites
Sickle Cell Trait and Other Hemoglobinopathies and Diabetes: Important Information for Physicians
Statistically speaking...Hemoglobin S and CAfrican Americans have an increased risk of inheriting sickle cell trait, the condition in which people have both hemoglobin A (HbA), the usual form of hemoglobin, and hemoglobin S (HbS), a variant. They also are at risk for having hemoglobin C (HbC), another variant. About one in 12 African Americans has sickle cell trait. About 14.7 percent of African Americans aged 20 years or older have diabetes.1 Therefore, many African Americans have both diabetes and sickle cell trait. Hemoglobin EPeople of Southeast Asian descent are at risk for having hemoglobin E (HbE), another hemoglobin variant. Prevalence of diabetes in Asian Americans varies among subpopulations. Studies have shown that some groups of Asian Americans in the United States are 1.5 to 2 times as likely to have diabetes as Caucasians of similar age.1 1 National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH). National diabetes statistics, 2007. Available at: www.diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm. Posted June 2008. Accessed July 1, 2008.
The A1C TestThe American Diabetes Association (ADA) does not recommend use of the A1C test for diagnosis of diabetes. Instead, the fasting plasma glucose test should be used to diagnose diabetes in children and nonpregnant adults. The ADA recommends use of the A1C test as part of the initial assessment and in continuing care of people with diabetes. Physicians should perform the A1C test
In addition, point-of-care testing for A1C can help in making timely decisions about changes in therapy. ADA Targets for the A1C Test
Effect of Hemoglobinopathies on A1C Test ResultsWith some assay methods, A1C tests in patients with hemoglobinopathies result in falsely high outcomes, overestimating actual average blood glucose levels for the previous 2 to 3 months. Physicians may then prescribe more aggressive treatments, resulting in increased episodes of hypoglycemia. Some assay methods used with some hemoglobinopathies may result in falsely low outcomes, leading to under-treatment of diabetes. The A1C test is not recommended for diagnosis of diabetes in the general population because it is not sufficiently sensitive. Also important, in patients with hemoglobinopathies, results may be falsely elevated, so physicians may erroneously conclude a patient has diabetes. Confirmation with a fasting blood glucose is required for a diagnosis of diabetes to prevent inappropriate treatment decisions.
Technically speaking...The A1C test measures the amount of glycated hemoglobin in the blood, which indicates average blood glucose levels over the preceding 2 to 3 months. Also called glycated hemoglobin or glycohemoglobin, the A1C test is based on the addition of glucose to hemoglobin over the typical 120-day life span of a red blood cell. Formation of glycated proteins is proportional to the concentration of glucose in the blood. The A1C test helps gauge risk of long-term complications; studies have demonstrated substantial reductions in long-term complications of diabetes with lowering of A1C.
HemoglobinopathiesHemoglobin molecules in red blood cells transport and distribute oxygen to cells throughout the body. Hemoglobin is composed of heme-the portion of the molecule containing iron-and globin-a protein made up of amino acid chains. Hemoglobin variants occur when mutations in the globin genes result in changes in the amino acids of the globin protein. Hundreds of variants have been identified; a small number of variants are common and have clinical significance. Hemoglobin variants are inherited in an autosomal recessive manner. Common Types of HemoglobinopathiesTable 1 summarizes the affected populations, prevalence, and outcomes of common hemoglobinopathies. These hemoglobinopathies may either falsely raise or lower A1C results, depending on the variant and the assay method. People who are heterozygous for a variant are said to have a trait or to be carriers and are usually asymptomatic. Those who are homozygous generally have a disease condition. Hemoglobin SC (HbSC) is a compound heterozygous condition, meaning that the patient has inherited genes for two variants: HbS from one parent and HbC from the other. Table 1. Common Hemoglobinopathies: Populations Affected, Prevalence, and Outcomes
1 National Heart, Lung, and Blood Institute, NIH. Sickle cell anemia. Available at: www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_All.html. Posted May 2007. Accessed June 27, 2007. 2 National Human Genome Research Institute, NIH. Learning about sickle cell disease. Available at: www.genome.gov/10001219. Posted February 2007. Accessed July 3, 2007. 3 Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clinical Chemistry. 2001;47(2):153-163.
Information about Assay Methods for Patients with HemoglobinopathiesThe NGSP provides a table on the NGSP website at http://www.ngsp.org/factors.asp describing the effects of frequently encountered Hb variants and derivatives on glycohemoglobin measurement for more than 25 assay methods. The NGSP website also includes a list of references for the information summarized in the table. According to the NGSP, as of July 2007, 14 percent of laboratories are using assay methods with clinically significant HbAS interference; 13 percent use methods with clinically significant HbAC interference. However, after upcoming changes in reagents expected to be complete by the end of 2008, only about 5 percent of laboratories will be using methods resulting in significant HbAS or HbAC interference. Alternative TestsPhysicians may wish to consider using other measures of average blood glucose levels, such as the fructosamine test, also called glycated serum protein or glycated albumin, with patients who have hemoglobinopathies where an accurate A1C result cannot be obtained. Serum proteins show average glucose levels over a much shorter period of time than the A1C test, usually about 2 to 3 weeks. Moreover, the fructosamine test is not standardized and the relationship of results of this test to glucose levels or risk for complications has not been established. Recent Changes in A1C ReportingA1C results will now be provided in the following ways:
Other Conditions that Can Affect A1C Test ResultsA number of other conditions, such as those that reduce the life span of red blood cells, can affect A1C results. Recent acute blood loss or hemolytic anemia can falsely lower A1C results. Intake of large amounts of vitamin C or vitamin E can falsely lower or elevate results. Iron deficiency anemia can falsely elevate results.
Points to Remember
Hope through ResearchParticipants in clinical trials can play a more active role in their own health care, gain access to new research treatments before they are widely available, and help others by contributing to medical research. For information about current studies, visit www.ClinicalTrials.gov. The U.S. Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this document are used only because they are considered necessary in the context of the information provided. If a product is not mentioned, the omission does not mean or imply that the product is unsatisfactory.
For More InformationNational Glycohemoglobin Standardization Program American Diabetes Association National Heart, Lung, and Blood Institute Health Information Center You may also find additional information about this topic by visiting MedlinePlus at www.medlineplus.gov. This publication may contain information about medications. When prepared, this publication included the most current information available. For updates or for questions about any medications, contact the U.S. Food and Drug Administration toll-free at 1-888-INFO-FDA (1-888-463-6332) or visit www.fda.gov. Consult your doctor for more information.
National Diabetes Information Clearinghouse
The National Diabetes Information Clearinghouse (NDIC) is a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK is part of the National Institutes of Health of the U.S. Department of Health and Human Services. Established in 1978, the Clearinghouse provides information about diabetes to people with diabetes and to their families, health care professionals, and the public. The NDIC answers inquiries, develops and distributes publications, and works closely with professional and patient organizations and Government agencies to coordinate resources about diabetes. Publications produced by the Clearinghouse are carefully reviewed by both NIDDK scientists and outside experts. This publication was originally reviewed by Charles M. Peterson, M.D., M.B.A., Director, Division of Blood Diseases and Resources at the National Heart, Lung, and Blood Institute, National Institutes of Health, and Randie R. Little, Ph.D., National Glycohemoglobin Standardization Program, University of Missouri School of Medicine. This publication is not copyrighted. The Clearinghouse encourages users of this publication to duplicate and distribute as many copies as desired. NIH Publication No. 09-6287
|